Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs reported its Q1 FY26 results (quarter ended June 30, 2025) with standalone net sales of Rs 3,412.20 lakhs (up ~2% from Rs 3,342.16 lakhs in Q1 FY25) and standalone profit after tax of Rs 479.41 lakhs (up ~18% from Rs 405.40 lakhs), translating to an EPS of Rs 2.98. On a consolidated basis, revenue jumped ~29% to Rs 4,313.98 lakhs, with consolidated PAT rising sharply from Rs 11.19 lakhs to Rs 226.25 lakhs. The company also announced a proposed Rights Issue of 13,98,463 equity shares at Rs 357 per share, aggregating ~Rs 49.93 crore, in a ratio of 2 rights shares for every 23 held. Other board items include re-appointment of Mr. Mukund Mehta as Managing Director for 5 years from April 1, 2026, the 33rd AGM on September 26, 2025, and re-appointment of cost and secretarial auditors. The statutory auditor C. Sharat & Associates has given an unmodified limited review opinion.
The results show modest standalone growth but a strong consolidated performance, partly aided by the foreign subsidiary. The Rs ~50 crore rights issue at a premium of Rs 357 per share (vs face value of Rs 10) signals upcoming equity dilution but also capital raising for growth. Shareholders should watch the rights issue record date and any near-term stock price pressure from the dilution.